Exclusive In-Licensing vs. Distributor Models: Choosing the Right Structure
When to appoint an exclusive licensing partner versus a multi-distributor network — risk, margin, and control trade-offs for pharma principals.
Foreign manufacturers often debate between exclusive in-licensing (where one partner holds the license and assumes market risk) and open distribution (multiple wholesalers competing on price). Each model suits different product profiles and strategic goals.
When exclusive in-licensing wins
Specialty products requiring KOL engagement, hospital tenders, pharmacovigilance infrastructure, and long registration cycles benefit from a single accountable partner. Inventa's in-licensing model includes dedicated medical affairs, regulatory, and commercial teams.
When distribution may suffice
Commodity APIs, mature OTC lines with established demand, or products with minimal regulatory burden may operate through selective distribution. We advise principals during due diligence — there is no one-size-fits-all answer.